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PURPOSEANDPATIENTSANDMETHODS: The 
purpose of this article is to report the experi- 
ence of three centers with combined hepatic and 
renal transplantation for pyridoxine-resistant 
primary hyperoxaluria type I (alanine:glyoxy- 
late aminotransferase [EC 2.6.1.441 deficiency), 
with particular emphasis on the selection crite- 
ria and timing of the operation. Nine patients 
with this inherited disease were treated by com- 
bined hepatic and renal transplantation. The 
former replaces the enzyme-deficient organ 
while the latter replaces the functionally affect- 
ed organ. 
RESULTS: One patient with gross systemic oxa- 
losis died in the immediate postoperative period 
and another died 8 weeks postoperatively of a 
generalized cytomegalovirus infection, having 
shown evidence of biochemical correction. One 
patient with particularly severe osteodystrophy 
at the time of the operation died 14 months post- 
operatively from renal failure due to progressive 
calcium oxalate nephrocalcinosis involving the 
transplanted kidney, plus thromboembolic dis- 
ease. He also had very extensive systemic oxalo- 
sis. A.n additional patient with severe osteodys- 
trophy died 9 months postoperatively. One 
patient developed hyper-rejection of the kidney 
and died later of gastrointestinal hemorrhage. 
The four long-term survivors (22 to 38 months) 
have remained asymptomatic from the stand- 
point of their renal disease, with resolution of 
any manifestations of systemic oxalosis that they 
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may have had. They are either employed or con- 
tinuing their education. 
CONCLUSIONS: A prolonged period of end-stage 
renal failure treated by dialysis regimens that 
are suitable for non-hyperoxaluric renal failure 
and extensive systemic oxalosis, particularly ox- 
alotic osteodystrophy, are poor prognostic fea- 
tures. We propose that hepatic transplantation 
should be considered as definitive treatment be- 
fore end-stage renal failure develops. This 
should be supplemented by renal transplantation 
with vigorous pre- and perioperative heinodialy- 
sis to deplete the body stores of oxalate. Al- 
though some authorities would reserve hepatic 
transplantation for patients in whom renal 
transplantation has failed, we suggest that com- 
bined liver and kidney transplantation is appro- 
priate in patients who have never had a renal 
graft. F’urthermore, the time has come to consid- 
er hepatic transplantation before any irrevers- 
ible renal damage has occurred in these 
patients. 
P rimary hyperoxaluria type I (PHI) is an autoso- ma1 recessively inherited inborn error of metab- 
olism [l] that is due to alanine:glyoxylate amino- 
transferase (AGT: EC 2.6.1.44) deficiency in the 
liver [2-41. There is increased synthesis and excre- 
tion of oxalate and glycolate with recurrent calcium 
oxalate urolithiasis and irreversible nephiocalcino- 
sis, which cause fatal renal failure. Calcium oxalate 
is deposited in many tissues (oxalosis) when oxalate 
retention and oxalate over-production combine to 
produce greatly increased oxalate ion concentration 
in the tissue fluids generally. Except for the treat- 
ment of pyridoxine-responsive variants of the dis- 
ease with pharmacologic doses of the vitamin [5,6], 
there had been no reports of biochemical correction 
of the disease until Watts et al [7] reported a case 
treated by combined hepatic and renal transplanta- 
tion (Patient 1 in this communication). Although 
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that patient died of a disseminated cytomegalovi- 
rus infection about 8 weeks after transplantation, 
the biochemical results encouraged further work by 
the same group, who were subsequently able to re- 
port a patient in whom combined liver and kidney 
transplantation led to near-normalization of plas- 
ma and urine metabolite levels and who was well 
and in regular employment 8 months postopera- 
tively [8] (Patient 2 in this communication). This 
was a notable advance in the management of a pre- 
viously untreatable disease and an example of the 
widening scope of liver transplantation as a means 
of enzyme replacement in the treatment of the in- 
born errors of metabolism. We now report experi- 
ence with combined hepatic and renal transplanta- 
tion for PHI from three centers with particular 
reference to the selection criteria and timing of the 
operation. We also discuss some aspects of pre- and 
perioperative management, the relative merits of a 
one- or two-stage operation, and evidence that the 
successfully treated patients gradually mobilize 
their systemic oxalate deposits. 
PATIENTS AND METHODS 
The case histories of the patients were all typical 
of PHI (Table I). All of these patients had had 
recurrent urinary stones and were in end-stage re- 
nal failure. In five patients, renal transplantation 
had failed, and one patient (Patient 4) had present- 
ed in end-stage oliguric renal failure 8 years before 
liver transplantation. All but one of the livers were 
completely, or almost completely (less than 2%), 
lacking in AGT activity (Table II). However, one 
patient (Patient 7) had a significant residual activi- 
ty of AGT (9%). There is no evidence that severe 
chronic renal failure has any effect on hepatic AGT 
activity. In fact, a diagnosis of PHI has been exclud- 
ed in three patients with end-stage renal disease by 
their completely normal liver AGT levels (Danpure, 
unpublished observations). Five patients had no 
detectable immunoreactive AGT protein and three 
had detectable but significantly reduced levels. Pa- 
tient 4 had normal levels of immunoreactive AGT 
protein despite having almost no AGT enzyme ac- 
tivity (Table II). 
Methods 
The analytical methods were derived from the 
following references: urine and plasma oxalate [9- 
111; urine and plasma glycolate [12]; glomerular fil- 
tration rate (GFR) by a standard isotopic EDTA- or 
DTPA-chelate technique, liver AGT (EC 2.6.1.44) 
and glutamate:glyoxylate aminotransferase (GGT; 
EC 2.6.1.4) enzyme activities [3]; and immunoreac- 
tive AGT protein [13]. The surgical procedures used 
are those described by Calne [14,15], and consist of 
orthotopic grafting of the liver to the hepatic fossa 
with anatomic anastomoses of the vessels and renal 
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transplantation to the right iliac fossa together with 
ureteric drainage into the bladder. 
RESULTS 
Table III shows the condition of the patients 
when they underwent transplanation and the out- 
come in each case. Patients 2,4, 5,6, and 7 all had 
good postoperative outcomes with satisfactory re- 
covery of liver function and adequate residual renal 
function. Patient 6 underwent combined liver and 
kidney transplantation despite systemic manifesta- 
tions of oxalosis that included congestive cardiomy- 
opathy due to myocardial oxalosis (confirmed by 
myocardial biopsy), complete heart block, and pe- 
ripheral neuropathy plus end-stage renal failure. 
He had been treated by continuous ambulatory 
peritoneal dialysis and one renal allograft for 18 
months. Since combined transplantation, his car- 
diomyopathy has resolved. Patient 4, who had un- 
dergone chronic hemodialysis for 7 years preopera- 
tively, presented in end-stage renal failure with 
very painful oxalotic osteodystrophy, which persist- 
ed and prevented normal activities. Postoperative- 
ly, he lost kidney function progressively because of 
calcium oxalate nephrocalcinosis in the grafted kid- 
ney and died 14 months later with extensive throm- 
boembolic disease (multiple pulmonary infarcts, 
cerebrovascular disease, inferior vena cava obstruc- 
tion) and heart failure. However, Patients 2, 5, 6, 
and 7 have been able to resume their regular em- 
ployment. Patient 3 had been in end-stage renal 
failure for 5 years. This had been treated initially by 
continuous ambulatory peritoneal dialysis and sub- 
sequently by hemodialysis regimens suitable for 
non-hyperoxaluric renal failure. Neither of these 
regimens was sufficient to prevent very severe sys- 
temic oxalosis, which showed as gangrenous toes, 
right bundle branch block, arterial calcification, os- 
teosclerosis, and synovitis. She became septicemic 
and died during the immediate postoperative 
period. 
Patient 8 had very severe osteodystrophy. He 
sustained bilateral pathologic fractures of the femo- 
ral necks and effusions into his right knee about 3 
months before the orthotopic liver transplantation. 
His postoperative course included cardiopulmo- 
nary complications, recurrent pleural effusions, a 
liver abscess, gastric ulcers, and generalized debility 
and wasting. He died 9 months after the liver 
transplantation. 
Patient 9 made a good immediate recovery from 
the hepatic and renal transplantation. The kidney 
functioned well and removed about 13,000 mmol of 
oxalate in 6 days. However, he developed hypera- 
cute rejection of the grafted kidney on the eighth 
TABLE11 
liver Enzyme Activities (rmol l hour-l l mg protein-l) 
Patient AGT GGT AGT” CRM 
Native liver 
: 0.70 42 0.58 1.01 0.03 4 - 
i 0.44 5 0.65 9 0.01 8 +++ 
; 0.54 1 0.90 68 i.06 +/-  
; 0.98 62 0.90 87 0.39 05 + 
9 0.53 0.72 0.05 
Donor liver 
+/- 
i 4.01 6 26 0.82 38 3.76 5 2 +tt tt  
Controls 
Mean 5.00 0.65 4.50 
Ranget 3.25-8.99 0.38-0.92 2.75-8.38 
Number 16 12 12 
I 
AGT = alanine:glyoxylate aminotransferase; GTT = glutamate:glyoxylate aminotransfer- 
ase; CRM = immunologically cross-reacting AGT (+++ = normal, - = not detectable). 
* AGT corrected for crossover [3] from GGT (AGT* = AGT - [GGT X 0.661). 
t From [3]. 
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postoperative day. The kidney was removed and 
hemodialysis was reinstituted. The liver continued 
to function well. His general condition, particularly 
the bone and joint pain, improved. However, he 
died of a massive gastrointestinal hemorrhage 
about 3 months postoperatively. 
“High-resolution x-ray powder diffraction analy- 
sis of bone and kidney tissue from Patients 8 and 9 
yielded x-ray diffraction maxima for calcium oxa- 
late monohydrate only. The widths of the diffrac- 
tion maxima for the bone calcium oxalate were nar- 
rower than for most calcium oxalate stone patterns. 
This implies that the calcium oxalate crystals 
[were] highly crystallized” (Dr. Neil S. Mandel). In 
oxalotic osteodystrophy, calcium oxalate replaces 
the bone calcium phosphates, and its high crystal- 
linity weakens the bones. 
Figure 1 shows the long-term changes in the 
plasma oxalate concentration, the urinary oxalate 
excretion, and the GFR in two of the patients (Pa- 
tients 2 and 7) who have made good long-term re- 
coveries and in Patient 4 who had advanced osteo- 
dystrophy when he received his transplant and who 
died after about 14 months. The changes in Patient 
5, who also had a good long-term outcome, were 
similar to those in Patients 2 and 7, with the plasma 
oxalate concentration decreasing toward normality 
over the course of several months and the urinary 
oxalate excretion values declining more slowly. The 
urinary glycolate values decreased immediately af- 
ter the transplantation as shown in Table IV. The 
available data for Patient 6 are more limited. His 
highest recorded plasma oxalate concentration was 
170 pmol/L 1 month before transplantation and 100 
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TABLE IV 
Comparative Values for the Urinary Excretion of Oxalate and 

















2.0 7 0.36 82
1.1 0 0.46 78
0.4 6 0.48 5 
0.5 0.54 
pmol/L and 28 pmol/L immediately before and af- 
ter hemodialysis, respectively, before the trans- 
plantation. Six months after transplantation, the 
plasma oxalate concentration and urinary oxalate 
excretion were 13 pmol/L and 2.9 mmo1/24 hours, 
respectively. 
Some of the data for Patient 2 have been pub- 
lished previously [8]. Data on Patient 5 have also 
been presented in preliminary form [16]. 
COMMENTS 
Figure 1. The short- and long-term changes in the urinary 
oxalate excretion (Uo,), plasma oxalate concentration (Pox), 
and glomerular filtration rate (GFR) in Patients 2 and 7 who 
had good postoperative recoveries and in Patient 4 who died 
about 14 months postoperatively. Horizontal lines -- and 
___--- show the upper limits of the reference ranges for Pox 
and U,,, respectively. 
The development of cyclosporine for the control 
of graft rejection has encouraged organ transplan- 
tation as a means of enzyme replacement therapy. 
In PHI, liver transplantation provides the missing 
enzyme (AGT) in the normal cellular and subcellu- 
lar locations. Because of the central role of the liver 
in intermediary metabolism, liver transplantation 
merits particular attention as a means of enzyme 
replacement for inborn errors of metabolism in 
which the metabolic lesion is specifically expressed 
in the liver. Hepatic failure, as in Wilson’s disease 
[17] and tyrosinemia type I [18], has heretofore 
been the main indication for the operation in this 
field. However, there is an expanding range of in- 
born errors of metabolism in which liver transplan- 
tation is becoming the preferred method of treat- 
ment because the allograft either synthesizes a 
factor for export to another organ, (e.g., cq-anti- 
trypsin deficiency) [19-211, or protects another or- 
gan from damage by a toxic metabolite as in the 
Crigler-Najjar syndrome [22]. Liver transplanta- 
tion can correct multiple secondary metabolic de- 
rangements as in glycogen storage disease type I 
[23]. Starzl and colleagues [20,21,24] have also suc- 
cessfully treated a child with familial hypercholes- 
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terolemia by a combined liver and heart transplan- 
tation [25]. 
The data presented in this paper support and 
amplify our previous conclusion that liver trans- 
plantation is potentially curative in PHI [7,8]. AGT 
is almost entirely liver-specific [26]. Therefore, 
transplantation of this organ should reintroduce 
nearly all of the body’s requirement for the enzyme. 
Liver transplantation lowered the glycolate levels 
immediately, whereas plasma and urinary oxalate 
levels reverted toward normal much more slowly in 
our patients. The metabolic fluxes of glyoxylate, 
oxalate, and glycoiate before and after liver trans- 
plantation are shown diagramatically in Figure 2. 
Glycolate does not form a highly insoluble calcium 
salt, so that once excessive synthesis is corrected, 
only the contents of the expanded soluble glycolate 
metabolic pool have to be excreted. Conversely, cal- 
cium oxalate is highly insoluble and is deposited in 
many tissues when oxalate retention due to ad- 
vanced renal failure is added to oxalate overproduc- 
tion. We interpret the more gradual decrease in the 
plasma and urine oxalate levels, with the urine lev- 
els lagging behind the plasma levels, to mobilization 
of the extrarenal oxalotic deposits. Cochat et aE [27] 
have shown that if the liver is transplanted when 
renal function is still good and before there is any 
systemic oxalosis, the plasma oxalate also normal- 
izes on the first postoperative day. The final extent 
to which calcium oxalate can be removed from the 
tissues remains to be assessed, but the results in 
Patient 6 show that cardiac oxalosis is potentially 
reversible. Better methods than those currently 
available for measuring the amount of oxalate in 
tissues in uiuo are needed. 
Patients with pyridoxine-resistant PHI who are 
treated by long-term hemodialysis or peritoneal di- 
alysis die from the effects of their systemic oxalosis 
because treatment regimens that control the ure- 
mia are not sufficient to keep up with the rate of 
oxalate production, at least in the long term [28]. 
This situation is exemplified by Patients 3 and 4 in 
the present study. The only definitive treatment 
options, unless the patient is highly responsive to 
pyridoxine, are either renal transplantation, which 
replaces the damaged target organ but leaves it ex- 
posed to the risk of further stone formation and/or 
nephrocalcinosis, or liver transplantation or a com- 
bined liver and kidney transplant. The last of these 
both normalizes the rate of oxalate production by 
correcting the metabolic lesion and replaces the 
damaged target organ. The results of renal trans- 
plantation alone have usually been poor, if it has 
been performed when the patient was already in 
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Figure 2. The metabolic fluxes of glyoxylate and its metabolic 
products in a normal subject and in a patient with PHI before 
and after liver transplantation. The thickness of the arrows 
represents the magnitude of the flux in the direction indicat- 
ed. Note that oxalate translocation from the soluble pool into 
the urine is still greater than normal after the liver transplan- 
tation while the oxalotic deposits are being mobilized. 
been exceptions [33-351. We have recently reviewed 
the existing literature and found that of 46 patients 
(not all of whom were specified as being either type 
I or type II) reported to have received 55 renal allo- 
grafts between them, only 20 survived 2 to 5 years, 
five for 5 to 10 years, and only one patient, who was 
shown to be pyridoxine responsive, for more than 10 
years. This contrasts sharply with the greater than 
75% l-year survival after renal transplantation for 
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other types of chronic renal failure [36]. Morgan et 
al [37] concluded from their studies of oxalate re- 
tention in hyperoxaluric and non-hyperoxaluric re- 
nal failure that, in primary hyperoxaluria, plans for 
renal transplantation should be ready by the time 
the GFR has decreased to about 20 to 25 
mL.min-l-1.73 rnm2, and Watts et al [38] have 
shown that early renal transplantation, preferably 
while the patient still has appreciable renal func- 
tion, plus very vigorous pre- and perioperative he- 
modialysis to deplete the miscible oxalate metabol- 
ic pool, improves graft survival. 
To date, our experience has shown us that the 
main complications after combined liver and kid- 
ney transplantation are infections, biliary leaks, 
and poor function of the grafted kidney, but not 
irreversible rejection of the .grafted liver. The out- 
come was excellent in Patients 2, 5, and 7, who 
underwent prompt and vigorous dialysis after the 
onset of their terminal illness and who received 
transplants as soon as possible, particularly before 
there was evidence of gross systemic oxalosis with 
severe bone disease and/or peripheral vascular in- 
sufficiency. The improved outlook for isolated renal 
grafts in PHI with early transplantation and vigor- 
ous perioperative dialysis [38] suggests that similar 
considerations should apply to the management of 
patients undergoing either hepatic transplantation 
or the combined operation. The grafted kidney is 
particularly at risk of damage from the high levels 
of plasma oxalate, as well as cyclosporine toxicity 
and immunologic rejection. Very large amounts of 
calcium oxalate can accumulate in the skeleton, in- 
creasing its crystallinity, thereby making it more 
fragile and producing bone pain. Three of the pa- 
tients who did poorly (Patients 3,4, and 8) because 
of postoperative renal failure had extensive oxalotic 
osteodystrophy. Further experience is needed to 
provide guidelines as to the degree of oxalotic osteo- 
dystrophy that should be a contraindication to 
transplantation. However, the successful outcome 
to combined hepatorenal transplantation plus in- 
tensive perioperative dialysis in a patient with car- 
diomyopathy and peripheral neuropathy as the sys- 
temic manifestations of oxalosis (Patient 61 shows 
that these patients should be considered for dual 
organ transplantation. The fact that the plasma ox- 
alate concentration returns to normal before the 
urinary oxalate excretion (which, however, ulti- 
mately normalizes) indicates that oxalotic deposits 
are mobilized from the tissues when excessive oxa- 
late synthesis is corrected by liver transplantation. 
It should be noted that the absence of chronic hepa- 
tobiliary disease and portal hypertension makes the 
technical demands of orthotopic liver transplanta- 
tion less daunting in these patients than in many 
severely ill patients who require liver 
transplantation. 
It could be argued that a renal allograft should be 
tried first and combined liver and kidney trans- 
plantation reserved until one renal transplantation 
has been destroyed by calculi and nephrocalcinosis 
or fails for some other reason. This proposition ig- 
nores the morbidity of recurrent stone disease, the 
risks of urinary tract infections, and, in particular, 
the risk of progressive potentially irreversible and 
lethal intrarenal crystallization of calcium oxalate 
and systemic oxalosis during episodes of obstruc- 
tive uropathy. Furthermore, since compromised re- 
nal function has been assessed as a poor prognostic 
indicator of outcome in liver transplantation [39], 
we favor either liver transplantation alone when 
there is stable and well-preserved renal function or 
the combined operation with vigorous periopera- 
tive hemodialysis as the definitive procedure when 
the patient is approaching end-stage renal disease. 
Patients whose GFR is in the range of 25 to 60 
mL.min-l-1.73 m-2 should be followed up closely 
with sequential assessment based on the rate of 
stone formation and the rate of loss of overall renal 
function as judged by serum creatinine and GFR 
measurements, along with plasma and urinary oxa- 
late levels. The plasma oxalate concentration is a 
particularly valuable guide with which to assess the 
imminence of the oxalotic phase of the illness. If the 
patient is to be treated by elective liver transplanta- 
tion alone, this should be done as soon as the disease 
has been shown to be acting aggressively. It should 
be stressed that renal failure progresses very slowly 
in some of these individuals, but the terminal phase 
is characteristically brief. Planning for a combined 
liver-kidney transplant should begin while the pa- 
tient still has appreciable renal function (GFR at 
least 20 to 25 mL.min-1~1.73 me2). This approach 
usually means that the liver and kidneys can be 
obtained from the same donor. However, it is uncer- 
tain whether this theoretic advantage is offset by 
possibly improved kidney graft survival after a two- 
stage procedure in which the metabolic lesion is 
corrected by liver transplantation, with renal trans- 
plantation after a period of vigorous hemodialysis 
to deplete the oxalate pool. McDonald et al [40] 
reported the use of a well-functioning renal allo- 
graft in a severely oxalotic patient to off-load oxa- 
late and improve the patient’s general condition 
before orthotopic liver transplantation. Given that 
some oxalate can be removed by very vigorous he- 
modialysis and the high probability that the renal 
graft will fail if the excessive oxalate production is 
not terminated, we do not regard this as the appro- 
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priate strategy in most cases. Both extensive oxalo- 
tic osteodystrophy with bone pain and prolonged 
dialysis using conventional regimens worsen the 
prognosis after liver-kidney transplantation. 
It is important to diagnose primary hyperoxa- 
luria early, to explore the possibility of pyridoxine 
sensitivity, and to institute vigorous medical man- 
agement and a conservative surgical policy that uti- 
lizes modern endoscopic and stone fragmentation 
techniques fully. 
The present studies establish PHI as a member of 
the group of inborn errors of metabolism in which 
liver transplantation is recommended to normalize 
a metabolic pathway and prevent damage to remote 
organs by a metabolite that accumulates behind a 
metabolic block in the patient’s own, otherwise nor- 
mal, liver. The patients in this series have all been 
in end-stage renal failure and hence in need of renal 
replacement. Most patients with PHI have rapidly 
progressive urolithiasis, and kidney transplanta- 
tion could be avoided if the liver was transplanted 
as soon as the enzymologic diagnosis had been made 
and it was clear that the patient’s disease was fol- 
lowing an aggressive clinical course. Alternative 
strategies, i.e., heterotopic auxiliary liver trans- 
plantation and the implantation of hepatocytes, are 
not considered to be viable alternatives to orthoto- 
pit liver transplantation because of competition 
from the patient’s own liver, which functions nor- 
mally except for the AGT deficiency. 
ADDENDUM 
More prolonged follow-up of the surviving pa- 
tients in this series and of other patients has shown 
that the urinary oxalate excretion, as well as the 
plasma oxalate concentration, becomes completely 
normal after a successful liver graft. 
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